• Cutmore L.C.
    • Brown N.F.
    • Raj D.
    • et al.

    Pancreatic Cancer UK Grand Challenge: developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma.

    Pancreatol Off J Int Assoc Pancreatol IAP Al. 2020; 20: 394-408doi.org/10.1016/j.pan.2020.02.006

    • Sarantis P.
    • Koustas E.
    • Papadimitropoulou A.
    • Papavassiliou A.G.
    • Karamouzis M.V.

    Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy.

    World J Gastrointest Oncol. 2020; 12: 173-181doi.org/10.4251/wjgo.v12.i2.173

    • Kamarajah S.K.
    • Bundred J.R.
    • Alrawashdeh W.
    • Manas D.
    • White S.A.

    A systematic review and network meta-analysis of phase III randomised controlled trials for adjuvant therapy following resection of pancreatic ductal adenocarcinoma (PDAC).

    HPB. 2020; 22: 649-659doi.org/10.1016/j.hpb.2019.12.001

    • Loveday B.P.
    • Lipton L.
    • Thomson B.N.

    Pancreatic cancer: an update on diagnosis and management.

    Aust J Gen Pract. 2019; 48: 826-831doi.org/10.31128/AJGP-06-19-4957

    • Siegel R.
    • Naishadham D.
    • Jemal A.

    Cancer statistics.

    CA A Cancer J Clin. 2012; 62 (2012): 10-29doi.org/10.3322/caac.20138

    • Wagner M.
    • Redaelli C.
    • Lietz M.
    • Seiler C.A.
    • Friess H.
    • Büchler M.W.

    Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma.

    Br J Surg. 2004; 91: 586-594doi.org/10.1002/bjs.4484

    • Konstantinidis I.T.
    • Warshaw A.L.
    • Allen J.N.
    • et al.

    Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a “true” R0 resection?.

    Ann Surg. 2013; 257: 731-736doi.org/10.1097/SLA.0b013e318263da2f

    • Fischer R.
    • Breidert M.
    • Keck T.
    • Makowiec F.
    • Lohrmann C.
    • Harder J.

    Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.

    Saudi J Gastroenterol Off J Saudi Gastroenterol Assoc. 2012; 18: 118-121doi.org/10.4103/1319-3767.93815

    • Jones R.P.
    • Psarelli E.-E.
    • Jackson R.
    • et al.

    Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial.

    JAMA Surg. 2019; 154: 1038-1048doi.org/10.1001/jamasurg.2019.3337

    • Butturini G.
    • Stocken D.D.
    • Wente M.N.
    • et al.

    Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials.

    Arch Surg Chic Ill 1960. 2008; 143 (discussion 83): 75-83doi.org/10.1001/archsurg.2007.17

    • Menon K.V.
    • Gomez D.
    • Smith A.M.
    • Anthoney A.
    • Verbeke C.S.

    Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP).

    HPB. 2009; 11: 18-24doi.org/10.1111/j.1477-2574.2008.00013.x

    • Verbeke C.S.
    • Menon K.V.

    Redefining resection margin status in pancreatic cancer.

    HPB. 2009; 11: 282-289doi.org/10.1111/j.1477-2574.2009.00055.x

    • Verbeke C.S.
    • Leitch D.
    • Menon K.V.
    • McMahon M.J.
    • Guillou P.J.
    • Anthoney A.

    Redefining the R1 resection in pancreatic cancer.

    Br J Surg. 2006; 93: 1232-1237doi.org/10.1002/bjs.5397

    • Esposito I.
    • Kleeff J.
    • Bergmann F.
    • et al.

    Most pancreatic cancer resections are R1 resections.

    Ann Surg Oncol. 2008; 15: 1651-1660doi.org/10.1245/s10434-008-9839-8

    • Martin R.C.G.
    • McFarland K.
    • Ellis S.
    • Velanovich V.

    Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma.

    J Am Coll Surg. 2012; 215: 361-369doi.org/10.1016/j.jamcollsurg.2012.05.021

    • Ye M.
    • Zhang Q.
    • Chen Y.
    • et al.

    Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis.

    HPB. 2020; 22: 821-832doi.org/10.1016/j.hpb.2020.01.001

    • Saccomandi P.
    • Lapergola A.
    • Longo F.
    • Schena E.
    • Quero G.

    Thermal ablation of pancreatic cancer: a systematic literature review of clinical practice and pre-clinical studies.

    Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group. 2018; 35: 398-418doi.org/10.1080/02656736.2018.1506165

    • Testoni S.G.G.
    • Healey A.J.
    • Dietrich C.F.
    • Arcidiacono P.G.

    Systematic review of endoscopy ultrasound-guided thermal ablation treatment for pancreatic cancer.

    Endosc Ultrasound. 2020; 9: 83-100doi.org/10.4103/eus.eus_74_19

    • Martin R.C.G.
    • McFarland K.
    • Ellis S.
    • Velanovich V.

    Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival.

    Ann Surg Oncol. 2013; 20: S443-S449doi.org/10.1245/s10434-012-2736-1

    • Kwon D.
    • McFarland K.
    • Velanovich V.
    • Martin R.C.G.

    Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.

    Surgery. 2014; 156: 910-920doi.org/10.1016/j.surg.2014.06.058

    • Martin R.C.G.

    Irreversible electroporation of stage 3 locally advanced pancreatic cancer: optimal technique and outcomes.

    J Vis Surg. 2015; 1: 4doi.org/10.3978/j.issn.2221-2965.2015.05.02

    • Zhang Z.
    • Li W.
    • Procissi D.
    • Tyler P.
    • Omary R.A.
    • Larson A.C.

    Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation.

    Nano. 2014; 9: 1181-1192doi.org/10.2217/nnm.13.72

    • Nielsen K.
    • Scheffer H.J.
    • Vieveen J.M.
    • et al.

    Anaesthetic management during open and percutaneous irreversible electroporation.

    Br J Anaesth. 2014; 113: 985-992doi.org/10.1093/bja/aeu256

    • Belfiore M.P.
    • Ronza F.M.
    • Romano F.
    • et al.

    Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: our preliminary experience.

    Int J Surg Lond Engl. 2015; 21: S34-S39doi.org/10.1016/j.ijsu.2015.06.049

    • Scheffer H.J.
    • Melenhorst M.C.A.M.
    • Vogel J.A.
    • et al.

    Percutaneous irreversible electroporation of locally advanced pancreatic carcinoma using the dorsal approach: a case report.

    Cardiovasc Intervent Radiol. 2015; 38: 760-765doi.org/10.1007/s00270-014-0950-x

    • Chan G.
    • Pua U.

    Irreversible electroporation of the pancreas.

    Semin Intervent Radiol. 2019; 36: 213-220doi.org/10.1055/s-0039-1693980

    • Frey G.T.
    • Padula C.A.
    • Stauffer J.A.
    • Toskich B.B.

    Intraoperative irreversible electroporation in locally advanced pancreatic cancer: a guide for the interventional radiologist.

    Semin Intervent Radiol. 2019; 36: 386-391doi.org/10.1055/s-0039-1697640

    • Paiella S.
    • Salvia R.
    • Ramera M.
    • et al.

    Local ablative strategies for ductal pancreatic cancer (radiofrequency ablation, irreversible electroporation): a review.

    Gastroenterol Res Pract. 2016; 2016: 4508376doi.org/10.1155/2016/4508376

    • He C.
    • Wang J.
    • Sun S.
    • et al.

    Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis.

    BMC Canc. 2019; 19: 394doi.org/10.1186/s12885-019-5607-3

    • Papoulas M.
    • Abdul-Hamid S.
    • Peddu P.
    • Cotoi C.
    • Heaton N.
    • Menon K.

    Irreversible electroporation in borderline resectable pancreatic adenocarcinoma for margin accentuation.

    J Surg Case Rep. 2018; 2018: rjy127doi.org/10.1093/jscr/rjy127

    • Yang P.-C.
    • Huang K.-W.
    • Pua U.
    • et al.

    Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - a multi-institutional clinical study in Asia.

    Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2020; 46: 811-817doi.org/10.1016/j.ejso.2019.12.006

    • Yan L.
    • Chen Y.-L.
    • Su M.
    • et al.

    A single-institution experience with open irreversible electroporation for locally advanced pancreatic carcinoma.

    Chin Med J. 2016; 129: 2920-2925doi.org/10.4103/0366-6999.195476

    • Flak R.V.
    • Stender M.T.
    • Jensen T.M.
    • et al.

    Treatment of locally advanced pancreatic cancer with irreversible electroporation - a Danish single center study of safety and feasibility.

    Scand J Gastroenterol. 2019; 54: 252-258doi.org/10.1080/00365521.2019.1575465

    • McCulloch P.
    • Cook J.A.
    • Altman D.G.
    • Heneghan C.
    • Diener M.K.
    • IDEAL Group

    IDEAL framework for surgical innovation 1: the idea and development stages.

    BMJ. 2013; 346: f3012doi.org/10.1136/bmj.f3012

    • Dindo D.
    • Demartines N.
    • Clavien P.-A.

    Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

    Ann Surg. 2004; 240: 205-213doi.org/10.1097/01.sla.0000133083.54934.ae

    • van Roessel S.
    • Kasumova G.G.
    • Tabatabaie O.
    • et al.

    Pathological margin clearance and survival after pancreaticoduodenectomy in a US and European pancreatic center.

    Ann Surg Oncol. 2018; 25: 1760-1767doi.org/10.1245/s10434-018-6467-9

    • Hank T.
    • Hinz U.
    • Tarantino I.
    • et al.

    Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.

    Br J Surg. 2018; 105: 1171-1181doi.org/10.1002/bjs.10842

    • Martin R.C.G.
    • Kwon D.
    • Chalikonda S.
    • et al.

    Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.

    Ann Surg. 2015; 262 (discussion 492-494): 486-494doi.org/10.1097/SLA.0000000000001441

    • Martin R.C.G.
    • Philips P.
    • Ellis S.
    • Hayes D.
    • Bagla S.

    Irreversible electroporation of unresectable soft tissue tumors with vascular invasion: effective palliation.

    BMC Canc. 2014; 14: 540doi.org/10.1186/1471-2407-14-540

    • Dunki-Jacobs E.M.
    • Philips P.
    • Martin R.C.G.

    Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas.

    J Am Coll Surg. 2014; 218: 179-187doi.org/10.1016/j.jamcollsurg.2013.10.013

    • Ansari D.
    • Kristoffersson S.
    • Andersson R.
    • Bergenfeldt M.

    The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy.

    Scand J Gastroenterol. 2017; 52: 1165-1171doi.org/10.1080/00365521.2017.1346705

    • Simmerman E.
    • Chung J.
    • Lawson A.
    • Kruse E.

    Application of irreversible electroporation ablation as adjunctive treatment for margin enhancement: safety and efficacy.

    J Surg Res. 2020; 246: 260-268doi.org/10.1016/j.jss.2019.06.010

    • Ruarus A.H.
    • Vroomen L.G.P.H.
    • Geboers B.
    • et al.

    Percutaneous irreversible electroporation in locally advanced and recurrent pancreatic cancer (PANFIRE-2): a multicenter, prospective, single-arm, phase II study.

    Radiology. 2020; 294: 212-220doi.org/10.1148/radiol.2019191109

    • Lafranceschina S.
    • Brunetti O.
    • Delvecchio A.
    • et al.

    Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer.

    Cancers. 2019; 11doi.org/10.3390/cancers11111718

    • Tasu J.-P.
    • Vesselle G.
    • Herpe G.
    • et al.

    Irreversible electroporation for locally advanced pancreatic cancer.

    Diagn Interv Imaging. 2016; 97: 1297-1304doi.org/10.1016/j.diii.2016.10.001

    • Su J.-J.
    • Su M.
    • Xu K.
    • et al.

    Postoperative inflammation as a possible cause of portal vein thrombosis after irreversible electroporation for locally advanced pancreatic cancer.

    World J Gastroenterol. 2017; 23: 6003-6006doi.org/10.3748/wjg.v23.i32.6003

    • Agnass P.
    • van Veldhuisen E.
    • van Gemert M.J.C.
    • et al.

    Mathematical modeling of the thermal effects of irreversible electroporation for in vitro, in vivo, and clinical use: a systematic review.

    Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group. 2020; 37: 486-505doi.org/10.1080/02656736.2020.1753828

    • Timmer F.E.F.
    • Geboers B.
    • Ruarus A.H.
    • et al.

    Irreversible electroporation for locally advanced pancreatic cancer.

    Tech Vasc Intervent Radiol. 2020; 23: 100675doi.org/10.1016/j.tvir.2020.100675

    • Lafranceschina S.
    • Brunetti O.
    • Delvecchio A.
    • et al.

    Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer.

    Cancers. 2019; 11doi.org/10.3390/cancers11111718

    • Kluger M.D.
    • Epelboym I.
    • Schrope B.A.
    • et al.

    Single-Institution experience with irreversible electroporation for T4 pancreatic cancer: first 50 patients.

    Ann Surg Oncol. 2016; 23: 1736-1743doi.org/10.1245/s10434-015-5034-x

    • Marsanic P.
    • Mellano A.
    • Sottile A.
    • De Simone M.

    Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma.

    Med Biol Eng Comput. 2017; 55: 1123-1127doi.org/10.1007/s11517-016-1603-9



  • Source link